The primary endpoint of BIO-RISE CHINA was presented at TCT 2021 Late Breaking Trials
November 7, 2021 | News | Bio-Rise China
This first-in-human study assessed the safety and efficacy of a Biolimus A9™ coated balloon and showed excellent results in small vessels with 0.16 mm late loss at 9 months.
TWO-YEAR RESULTS FROM THE BIOMATRIX ALPHA REGISTRY PUBLISHED IN JOURNAL OF INTERVENTIONAL CARDIOLOGY
April 29, 2021 | News | BioMatrix Alpha
MACE 7.2% Cardiac Death 1.3% MI 2.8% & ST 1.1%.
CE Mark Approval for Biolimus A9™ Coated Cobalt Chromium Coronary Stent System BioFreedom™ Ultra
October 19, 2020 | News | BioFreedom™ Ultra
BioFreedom™ Ultra is Biosensors International new, novel thin strut CoCr polymer and carrier-free Drug Coated Stent with Biosensors proprietary limus BA9™, a highly lipophilic anti-restenotic drug, developed specifically for use in coronary vascular applications. BioFreedom™ Ultra successfully extends the LEADERS FREE legacy in LEADERS FREE III.
The 1st DCS/DES approved with 1 month DAPT in High Bleeding Risk patients
December 3, 2020 | News | BioFreedom™ Family
BioFreedom™ since 2015 (CE marked) and now
BioFreedom™ ULTRA is available in CoCr.
The primary endpoint of LEADERS FREE III was presented at PCR e-course 2020
June 27,2020 | News | BioFreedom™ Ultra
The study evaluates the safety and efficacy of the novel thin-strut (84µm) CoCr polymer-free DCS BioFreedom™ Ultra in HBR patients. Details are available in Professor Eberli’s presentation.
BIOSENSORS INTERNATIONAL ANNOUNCES ENROLLMENT OF FIRST PATIENT IN NEW PIVOTAL DRUG COATED BALLOON TRIAL "REFORM".
August 11, 2020 | News | Drug-eluting Balloons
The REFORM trial, utilises a Biolimus A9™ coated balloon, the latest development in Biosensors International balloon technology.